Project Grant R03DE034425
Award Date
7/15/25
Completion Date
7/14/27
Dollars Obligated
$315K
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $451,000.00 to the University of Chicago to conduct research aimed at deciphering the mechanisms behind patient responses to a novel immunotherapy targeting human papillomavirus (HPV) associated head and neck cancer. The key objectives of this 2-year research project are to leverage patient tumor biopsies, plasma samples,...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $642,488 to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The funding will support a 5-year research project focused on understanding the mechanisms by which human papillomavirus (HPV) promotes immune evasion in head and neck squamous cell carcinomas (HNSCC)....
This $329,737 Project Grant awarded on September 12, 2023 by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is supporting the development of a rapid, easy-to-use diagnostic platform for the point-of-care detection of high-risk HPV in saliva. The grantee, Innotech Precision Medicine, Inc., is working to create an innovative electrochemical biosensor that combines CRISPR-Cas12 technology with their...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $204,688 to The Johns Hopkins University from May 1, 2025 to April 30, 2027. The project aims to evaluate and compare the ability of Salmonella-derived nanoparticles (SAL-9RE7 and SOMV-9RE7) to mediate tumor control and induce HPV E7-specific T cell immunity. It will also evaluate the potency of a combination treatment...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to the University of Arizona in the amount of $118,763 for the period of September 1, 2024 to August 31, 2026. The grant will support Dr. Robert Jackson's research focused on assessing the role of human papillomavirus type 16 (HPV16) in transforming versus productive infections in oral epithelial tissues. The research aims to characterize the viral...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $148,280 to Childrens Hospital Medical Center in Cincinnati, Ohio to study the role of the ERBB2 protein in human papillomavirus (HPV)-induced pathologies. The research aims to spatially resolve ERBB2 expression, activation, and downstream signaling in 3D organotypic epithelial raft models of HPV-positive and HPV-negative cells. The study will also define whether ERBB2 is...
This federal Project Grant award of $533,707, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how the human papillomavirus (HPV) evades the body's natural defenses and persists in infected cells. The primary goal is to elucidate the mechanism by which the HPV E7 oncoprotein activates the YAP1 signaling pathway, enabling HPV-infected cells to remain in the...
This Cooperative Agreement award of $638,903, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to validate a novel prognostic biomarker that captures tumor biology and heterogeneity in over 1,000 diverse human papillomavirus positive (HPV+) oropharyngeal cancer (OPC) patients. The goal is to guide clinical decision-making and reduce treatment-related toxicity and morbidity. Key products and...
This federal Project Grant award of $2,740,126, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the mechanisms by which HIV infection contributes to the development of oropharyngeal cancer (OPC) in people living with HIV (PWH). The key objectives are to: 1) Determine the HPV types present in OPC from PWH and how T cell-mediated anti-tumor immunity is impaired;...